Avant Research Associates — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,278	1
2024	Research	$8,259	1
2023	Research	$37,776	2
2021	Research	$7,500	1
2020	Research	$2,500	1
2019	Research	$43,122	4

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $53,535 4 payments
Hikma Pharmaceuticals USA $45,622 5 payments
GlaxoSmithKline, LLC. $1,278 1 payment

Studies the money was for Research payments · program years 2019–2025

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $53,435 3 payments
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $13,776 1 payment
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $12,845 1 payment
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $9,000 1 payment
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $7,500 1 payment
Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study $2,500 1 payment
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para $1,278 1 payment
A 12-Week Randomized, Participant-And Investigator-Blinded, Placebo-Controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled Csj117 in Adults With Chronic Obstructive Pulmonary Disease (COPD) $100 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.